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Acute respiratory infections are responsible for more than 4 million deaths each year. Neutrophils play an 
essential role in the innate immune response to lung infection. These cells have an armamentarium of pattern 
recognition molecules and antimicrobial agents that identify and eliminate pathogens. In the setting of infec-
tion, neutrophil triggering receptor expressed on myeloid cells 1 (TREM-1) amplifies inflammatory signaling. 
Here we demonstrate for the first time that TREM-1 also plays an important role in transepithelial migra-
tion of neutrophils into the airspace. We developed a TREM-1/3–deficient mouse model of pneumonia and 
found that absence of TREM-1/3 markedly increased mortality following Pseudomonas aeruginosa challenge. 
Unexpectedly, TREM-1/3 deficiency resulted in increased local and systemic cytokine production. TREM-1/3– 
deficient neutrophils demonstrated intact bacterial killing, phagocytosis, and chemotaxis; however, histo-
logic examination of TREM-1/3–deficient lungs revealed decreased neutrophil infiltration of the airways. 
TREM-1/3–deficient neutrophils effectively migrated across primary endothelial cell monolayers but failed 
to migrate across primary airway epithelia grown at the air-liquid interface. These data define a new function 
for TREM-1 in neutrophil migration across airway epithelial cells and suggest that it amplifies inflammation 
through targeted neutrophil migration into the lung.
Introduction
Acute respiratory infections have been described as the forgot-
ten pandemic, responsible for 4.5 million deaths annually. Effec-
tive neutrophil migration into the intrapulmonary airspace is 
essential for pathogen elimination in the lung. Neutrophils pos-
sess diverse tools, including ROS intermediates, antimicrobial 
peptides, neutrophil extracellular traps, and numerous pattern 
recognition receptors (PRRs), that facilitate the response to de 
novo infections (1, 2). Moreover, neutrophils participate in B cell 
maturation and differentiation, Th17 responses, dendritic cell 
maturation, natural killer cell responses, and IL-10 production, 
revealing a regulatory role for neutrophils (2). Like other cells 
of the innate immune system, neutrophils express several large 
genetically encoded receptor families that act to detect and elimi-
nate pathogens. These families include the TLR family, C-type 
lectin receptors, and the triggering receptor expressed on myeloid 
cells (TREM) family (3–5).
TREM-1, which was initially discovered on human neutrophils 
and monocytes, has been studied in patients with pneumonia and 
sepsis (6, 7). Increased TREM-1 levels in bronchoalveolar lavage 
(BAL) fluid strongly correlate with ventilator-associated pneumo-
nia, and systemic levels of TREM-1 in the serum serve as a marker 
of sepsis (8, 9). TREM-1 has been shown to amplify the inflam-
matory cascade in response to infection (10). Surface expression 
of TREM-1 is increased in response to LPS and other microbial 
products in vitro. Antibody-mediated crosslinking of TREM-1 
induces modest cellular activation and proinflammatory cytokine 
secretion. Furthermore, when TREM-1 acts in concert with PRRs, 
there is a synergistic increase in inflammatory signaling (10–13). 
Such data suggest that TREM-1 functions as an amplifier of the 
immune response in the context of microbial infection.
During the process of pathogen recognition and elimination, 
excessive cytokine and chemokine release can lead to extensive tis-
sue damage and even death (14, 15). Therapeutic agents designed to 
temper the deleterious consequences of host-pathogen interactions 
result in a survival benefit in some experimental models of endo-
toxemia. On the other hand, it is clear that some inflammation is 
necessary for bacterial killing in vivo. Accordingly, numerous clini-
cal examples of impaired neutrophil function are linked to increased 
rates of infection and death, including chronic granulomatous dis-
ease (CGD), neutropenic fever, and lymphocyte adhesion deficiency. 
However, animal studies indicate that effective bacterial clearance can 
be achieved in the setting of decreased inflammation (16, 17). In the 
case of TREM-1, blockade of TREM-1 has been achieved by admin-
istering soluble forms of TREM-1, small molecule blocker (LP-17), 
or RNA silencing (10, 18, 19). All three of these interventions result 
in decreased systemic cytokine production and improved survival 
in mice. Taken together, these animal studies of TREM-1 blockade 
suggest that it may be possible to modulate the TREM-1 pathway to 
decrease inflammation without sacrificing bacterial control.
We hypothesized that TREM-1 deficiency would decrease 
inflammation and improve survival in a murine pneumonia 
model. Paradoxically, we found that TREM-1/3 deficiency resulted 
in a marked increase in mortality. Our data suggest that impaired 
neutrophil transepithelial migration is the mechanism underlying 
the failure to clear lung bacteria, resulting in increased mortality 
with TREM-1/3 deficiency. These findings identify a novel role for 
TREM-1 in neutrophil epithelial transmigration in addition to its 
established role in amplifying inflammatory signaling.
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Results
Generation of TREM-1–deficient mice. The goal of these studies was 
to elucidate the role of TREM-1 in pneumonia using a mouse 
model of TREM-1 deficiency. In mice, the Trem1 gene is adjacent 
to a highly homologous gene, Trem3, which likely arose from a 
duplication event. The two receptors have similar cellular distri-
bution and associate with DAP12. Further suggesting that these 
two proteins have redundant functions in the mouse, functional 
studies in our laboratory and others show that both molecules 
are amplifiers of inflammatory signaling (20). In contrast, Trem3 
is a pseudogene in humans, and therefore no functional overlap 
exists. Thus, to model the effect of blocking TREM-1 in humans, 
we generated a TREM-1/3–deficient mouse. To abrogate expres-
sion of functional TREM-1 and TREM-3 proteins, we made a 
targeting construct in which an 8.8-kb fragment containing 
most of exon 3 and exon 4 of Trem1 as well as exon 1 of Trem3 
was replaced with a MC1neopA gene flanked by loxP sites (Sup-
plemental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI64181DS1). This effectively deleted 
the transmembrane region of TREM-1 in addition to the start 
site and first domain of TREM-3. Chimeras generated from a 
correctly targeted clone were bred to transgenic mice express-
ing Cre under the CMV promoter on a C57BL/6 background to 
delete the MC1neopA gene. Homozygote TREM-1/3–deficient 
mice failed to express TREM-1 and TREM-3 proteins (Supple-
mental Figure 2). Inheritance of this mutation followed expect-
ed Mendelian distribution, with 25% homozygotes, 21% WT, 
and 54% heterozygotes assayed (n = 229). Flow cytometric analy-
sis using lineage markers revealed no significant differences in 
the percentages of circulating leukocyte populations as a result 
of Trem1 and Trem3 deletion (Supplemental Figure 3).
TREM-1/3 is essential for host survival following pulmonary challenge with 
P. aeruginosa. To examine the role of TREM-1 in survival in response 
to pneumonia, we challenged TREM-1/3–deficient mice, WT lit-
termate controls, or WT C57BL/6 mice intratracheally with P. aeru-
ginosa. Survival analysis performed using Gehan-Breslow-Wilcoxon 
statistical tests showed a significant increase in mortality in TREM-
1/3–deficient mice as compared with WT mice, with χ2 = 18.75 
and P < 0.0001 (Figure 1A). Additional clinical indicators of sepsis 
including body temperature and evidence of end-organ damage 
were monitored. TREM-1/3–deficient animals were hypothermic 
(Figure 1B, P = 0.0001), consistent with the development of sys-
temic disease. TREM-1/3–deficient animals also showed evidence 
of end-organ damage in the form of transaminitis as measured by 
serum alanine aminotransferase (ALT) levels, whereas WT animals 
had no elevation (Figure 1C). These data indicate that TREM-1/3 
expression is essential for host survival following pulmonary chal-
Figure 1
TREM-1/3 expression is essential for host survival following P. aeruginosa challenge. (A) Kaplan-Meier survival plot of TREM-1/3–deficient 
(n = 35, 4 experiments) and WT mice (n = 26, 4 independent experiments) following intratracheal challenge with P. aeruginosa (*P = 0.0001). 
(B) Body temperature was measured 14 hours after infection with P. aeruginosa (*P = 0.0001) (n = 95 mice, 9 experiments). (C) As a marker of 
liver damage, ALT levels were measured 14 hours after intratracheal challenge with P. aeruginosa (n = 11).
Figure 2
TREM-1/3–deficient mice fail to eradicate P. aeruginosa following pul-
monary challenge. (A) CFU of P. aeruginosa in BAL fluid at 4 hours after 
infection in WT and TREM-1/3–deficient mice (n = 12, 1 experiment). 
(B) CFU of P. aeruginosa in BAL from WT and TREM-1/3–deficient 
mice 14 hours after infection (*P = 0.011) (n = 27, 2 independent experi-
ments). (C) CFU of P. aeruginosa recovered in whole lung homogenates 
from WT and TREM-1/3–deficient mice 14 hours after infection 
(*P = 0.036) (n = 14, 1 experiment). (D) CFU of P. aeruginosa recov-
ered from cardiac puncture 14 hours after inoculation in TREM-1/3– 
deficient and WT mice (n = 27, 2 independent experiments).
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lenge with P. aeruginosa. Challenge with heat-killed P. aeruginosa 
resulted in no mortality in WT or TREM-1/3–deficient mice (n = 4 
in each group, data not shown), suggesting that the difference in 
survival observed in the TREM-1/3–deficient mice was due to a 
decrease in the ability to control active infection and not increased 
inflammation in the setting of endotoxin challenge.
TREM-1/3–deficient animals fail to eradicate P. aeruginosa. To assess 
bacterial clearance, we performed bacterial sampling of BAL 
fluid using whole lung lavage on anesthetized animals at either 
4 or 14 hours after infection. At 4 hours after infection, both 
TREM-1/3–deficient and WT BAL fluid (Figure 2A) showed 
growth of P. aeruginosa. However, at 14 hours after infection, 
P. aeruginosa CFU were higher in the lungs of TREM-1/3–deficient 
animals (Figure 2B, P = 0.011). In addition, P. aeruginosa CFU were 
also significantly higher in cultures obtained from whole lung 
suspensions generated 14 hours after infection in TREM-1/3–
deficient as compared with WT mice (Figure 2C, P = 0.036). Next, 
blood was obtained by cardiac puncture 14 hours after infection 
to assess systemic bacteremia (Figure 2D). TREM-1/3–deficient 
animals had a higher incidence of bacteremia (53% TREM-1/3–
deficient vs. 27% WT). Thus, TREM-1/3–deficient mice fail to 
eradicate P. aeruginosa infection locally, resulting in systemic dis-
semination of bacteria and death.
TREM-1/3–deficient neutrophils kill P. aeruginosa effectively in vitro. 
To assess whether impaired neutrophil function was the mecha-
nism for poor local and systemic control of P. aeruginosa in the 
TREM-1/3–deficient animals, we measured phagocytosis and in 
vitro neutrophil killing of P. aeruginosa. First, phagocytosis was 
measured using Texas red–zymosan. Neutrophils were isolated 
from TREM-1/3–deficient and WT bone marrow (pooled 3–5 per 
group). There were no significant differences in the percentage of 
neutrophils that ingested particles (Figure 3A) or in the number 
of particles phagocytized per neutrophil as determined by the 
geometric mean of Ly6G-positive cells (Figure 3B). To distinguish 
between intracellular and extracellular particles, we performed 
Figure 3
TREM-1/3–deficient neutrophils effectively kill P. aeruginosa. (A) TREM-1/3–deficient and WT neutrophil phagocytosis of Texas red–labeled zymo-
san particles was quantitated as the percentage of cells ingesting particles (2 independent experiments; pooled neutrophils from 2–3 mice per 
group). (B) The relative number of Texas red–labeled particles ingested per neutrophil was also quantified using the geometric MF of Texas red– 
positive TREM-1/3–deficient and WT neutrophils. (C) The ability of TREM-1/3–deficient and WT bone marrow neutrophils to kill P. aeruginosa was 
measured (3 independent experiments; pooled neutrophils from 2–3 mice per group).
Figure 4
TREM-1/3–deficient mice have decreased histologic evidence of pneu-
monia following P. aeruginosa challenge. (A and B) Representative 
H&E-stained lungs from (A) WT or (B) TREM-1/3–deficient mice 14 
hours after infection with P. aeruginosa. Original magnification, ×10; 
inset, ×60. Arrows indicate areas of necropurulent foci. ×10 scale bar: 
140 μm; ×60 scale bar: 50 μm. (C) Leukocyte infiltration score in lungs 
from WT and TREM-1/3–deficient mice 14 hours after infection (n = 10 
mice, *P = 0.016). (D) Necrotic foci score in lungs of WT and TREM-1/3– 
deficient mice 14 hours after infection (n = 10 mice, *P = 0.05). Error 
bars indicate SEM.
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fluorescence quenching with trypan blue (21). No significant dif-
ference in quenching was detected between WT and TREM-1/3–
deficient neutrophils (Supplemental Figure 4). Next, to examine 
the capacity of murine neutrophils to kill P. aeruginosa, we isolated 
neutrophils and co-incubated them with bacteria (22). At 30 min-
utes, more than 90% of the bacteria were ingested. Non-ingested 
bacteria were killed with gentamicin, as previously described (23). 
Intracellular bacterial killing was assessed at 30, 60, and 90 min-
utes after exposure to gentamicin. There was no significant differ-
ence in the ability of TREM-1/3–deficient and WT neutrophils to 
kill P. aeruginosa (Figure 3C). Finally, to determine how TREM-1/3 
deficiency affects neutrophil ROS production, we isolated neutro-
phils from WT and TREM-1/3–deficient animals and stimulated 
them with opsonized zymosan and PMA. In the presence of no 
agonist, neither set of neutrophils produced ROS (Supplemental 
Figure 5), indicating that the neutrophils had not been activated 
in the isolation process. However, TREM-1/3–deficient neutro-
phils had a 50% reduction in ROS production in response to opso-
nized zymosan as compared with WT neutrophils (Supplemental 
Figure 5), whereas ROS production in response to PMA was intact 
(Supplemental Figure 5). It is well established that neutrophils 
eliminate P. aeruginosa through a number of O2-independent path-
ways, including bactericidal/permeability-increasing protein (BPI), 
proteases, lipases, and defensins (24). In fact, neutrophils isolated 
from patients with CGD (an inherited defect in NADPH oxidase 
resulting in severely impaired ROS production) effectively kill 
P. aeruginosa, indicating that ROS production is not required in order 
to effectively kill this organism (24). Therefore, given the in vitro 
killing data, the striking in vivo phenotype in the TREM-1/3–defi-
cient mice is likely not due to an intrinsic neutrophil killing defect.
Lungs from TREM-1/3–deficient mice have decreased histologic evidence 
of pneumonia. Histologic examination of lungs harvested from live 
mice at 14 hours after infection showed an unexpected difference. 
Lung tissue from 5 TREM-1/3–deficient animals and 5 WT ani-
mals was analyzed by a veterinary pathologist unaware of sample 
identities. The degree of inflammation was quantified as described 
in the Methods. TREM-1/3–deficient animals had less evidence 
of inflammation/pneumonia as compared with WT animals 
(Figure 4, A and B). Moreover, TREM-1/3–deficient animals had 
reduced leukocyte infiltration by morphometry (P = 0.016) and 
fewer necropurulent foci (P = 0.05) present in the lungs as com-
pared with WT animals (Figure 4, C and D, respectively). Taken 
together, these data indicate that, despite increased bacterial load 
and higher mortality, TREM-1/3–deficient animals have impaired 
pulmonary inflammation in response to P. aeruginosa challenge.
TREM-1/3–deficient animals have decreased neutrophils in the airway. 
To assess leukocyte migration into the lung, first we asked whether 
there was a defect in wbc translocation into the lung. Single-cell 
suspension of lungs from WT and TREM-1/3–deficient animals 
were prepared to quantitate total lung wbc. TREM-1/3–deficient 
Figure 5
Quantification of neutrophils in lung compartments following P. aeruginosa challenge. (A) Quantification of total wbc populations in single-cell 
suspensions from lungs of WT and TREM-1/3–deficient mice 14 hours after infection (n = 15, *P = 0.001). (B) Quantification of neutrophils present 
in BAL of WT and TREM-1/3–deficient mice 14 hours after infection (n = 20, *P = 0.004, 2 independent experiments) (C) Morphometric analysis of 
the neutrophils in the interstitium of terminal bronchioles from the lungs of WT and TREM-1/3–deficient mice (n = 14, *P = 0.001). (D) Stereotactic 
analysis of alveolar neutrophils from the lungs of WT and TREM-1/3–deficient animals (n = 14, P = 0.79). Error bars indicate SEM.
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Figure 6
TREM-1/3–deficient animals have intact local cytokine 
and chemokine production. BAL: Indicated chemo-
kine levels were measured in BAL fluid from WT 
and TREM-1/3–deficient mice 14 hours after infec-
tion. *CXCL1/KC: P = 0.048, CCL2/MCP: P = 0.017, 
and CXCL2/MIP-2: P = 0.004 (n = 27, 3 independent 
experiments). Lung homogenates: Cytokine and che-
mokine profiles from WT and TREM-1/3–deficient lung 
homogenates. *IL-1α: P = 0.038, IL-1β: P = 0.038, IL-6: 
P = 0.015, IL-10: P = 0.05, IL-17: P = 0.022, TNF-α: 
P = 0.007, CXCL1/KC: P = 0.02, CXCL2/MIP-2: P = 0.012, 
and CCL2/MCP-1: P = 0.035 (n = 22, 2 independent 
experiments). Plasma: Plasma cytokine and chemo-
kine levels in WT and TREM-1/3–deficient mice at 
14 hours after inoculation with P. aeruginosa. *G-CSF: 
P = 0.0004, IL-6: P = 0.0001, IL-1α: P = 0.0448, 
CCL5/RANTES: P = 0.022, TNF-α: P = 0.0072, IL-10: 
P = 0.0007, CXCL1/KC: P = 0.0011, CXCL2/MIP-2: 
P = 0.0018, and CCL2/MCP-1: P = 0.0002 (n = 28, 3 
independent experiments). Error bars indicate SEM.
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animals had similar numbers of eosinophils, macrophages, NK 
cells, CD4+ T cells, CD8+ T cells, and B cells (Figure 5A, n = 15). 
Unexpectedly, the number of total lung neutrophils was sig-
nificantly higher in TREM-1/3–deficient animals (Figure 5A, 
P = 0.001). Therefore, despite having more total lung neutrophils, 
TREM-1/3–deficient mice failed to develop pneumonia with con-
solidation and were unable to clear P. aeruginosa lung infection, 
resulting in a marked increase in mortality.
Next, we determined using BAL whether TREM-1/3–deficient mice 
have defective neutrophil translocation into the airspace. More than 
96% of all cells from the BAL fluid of both groups were Ly6G posi-
tive and CD115 negative (data not shown), consistent with murine 
neutrophil identity. TREM-1/3–deficient mice had a 50% reduction 
in the number of airway neutrophils (Figure 5B, P = 0.004), suggest-
ing impaired migration of neutrophils into the airspace. We then 
used a stereological approach to further localize neutrophils in the 
compartments of the lung by specifically examining the interstitium, 
the airway lumen (terminal bronchioles), and the alveolar space. To 
assess the location of neutrophils in the distal airways, we identified 
terminal bronchioles and a sequestration index was calculated to 
assess the relative number of neutrophils in the interstitium versus 
the distal airway lumen. Terminal bronchioles from TREM-1/3–
deficient mice had a higher sequestration index as compared with 
WT mice (Figure 5C, n = 13, P = 0.001), indicating that a higher pro-
portion of neutrophils was present in the interstitial space as com-
pared with the lumen and suggesting a neutrophil migratory block 
into the bronchiolar airway. There was no detectable difference in 
the number of neutrophils in the alveolar compartment in WT and 
TREM-1/3–deficient mice (Figure 5D). The features of consolida-
tion and alveolar collapse were at times confounding issues, and it 
remains unclear whether a migratory block at the alveolar level exists 
in TREM-1/3–deficient mice. Taken together, the histologic data and 
BAL data indicate that, with TREM-1/3 deficiency, there is a defect in 
neutrophil migration into the airspace.
TREM-1/3–deficient mice have increased cytokine production both local-
ly and systemically following P. aeruginosa challenge. Because TREM-1 
acts synergistically with TLR and other PRRs to augment proin-
flammatory cytokine production, we hypothesized that a blunted 
cytokine response to infection with P. aeruginosa would be respon-
sible for decreased airway neutrophils in TREM-1/3–deficient 
animals. Cytokines were sampled in the plasma, BAL fluid, and 
total lung homogenates. To avoid survivor bias, all samples were 
collected at 14 hours following infection, when all animals in both 
groups were alive. First, to ascertain whether decreased neutro-
phil migration was the result of a deficiency in local chemokine 
production, we obtained BAL fluid from infected mice. CXCL1/
KC, CXCL2/MIP-2, and CCL2/MCP were elevated in TREM-1/3–
deficient as compared with WT mice, consistent with sufficient 
local production of chemoattractants (Figure 6, BAL: P = 0.048, 
P = 0.017, and P = 0.004, respectively). In separate experiments, 
total tissue cytokine levels were measured in lungs harvested from 
anesthetized TREM-1/3–deficient and WT mice after perfusion 
with PBS from the right ventricle to remove intravascular blood 
(Figure 6, Lung homogenates). TREM-1/3–deficient mice had 
higher levels of IL-1α (P = 0.038), IL-1β (P = 0.038), IL-6 (P = 0.015), 
IL-10 (P = 0.05), IL-17 (P = 0.022), and TNF-α (P = 0.007) and 
chemokines CXCL1/KC (P = 0.02), CXCL2/MIP-2 (P = 0.012), 
and CCL2/MCP-1 (P = 0.035). Based on these results and those 
shown in Figures 4 and 5, we conclude that despite elevated local 
cytokines and chemokines, TREM-1/3–deficient animals have 
ineffective accumulation of neutrophils in the airway lumen.
Additionally, systemic cytokine levels were measured (Figure 6). The 
TREM-1/3–deficient mice had statistically significant increases in 
the proinflammatory cytokines G-CSF, IL-6, IL-1α, CCL5/RANTES, 
TNF-α, IL-12p40 (P = 0.004, data not shown), and IL12-p70 (P = 0.020, 
data not shown); increased levels of chemoattractants CXCL1 /KC, 
CCL2/MCP-1, CXCL2/MIP-2; and increased anti-inflammatory 
cytokine IL-10. These data indicate that the cytokine production 
was not impaired in the setting of infection despite the loss of the 
TREM-1/3 amplifying pathway. Moreover, these data indicate that 
impaired cytokine production was not responsible for the decrease 
in neutrophils in the airway lumen of TREM-1/3–deficient animals.
TREM-1/3–deficient neutrophils have normal cell death. To investigate 
whether the diminished number of neutrophils in the airways of 
TREM-1/3–deficient animals was due to increased cell death, we 
isolated neutrophils from TREM-1/3–deficient and WT animals 
and determined cell death by propidium iodide uptake as previ-
ously described (25). We observed no significant difference in the 
percentage of neutrophils undergoing cell death spontaneously or 
Figure 7
TREM-1/3–deficient neutrophils undergo cell death at rates similar 
to those of WT neutrophils. (A and B) WT and TREM-1/3–deficient 
neutrophil cell death was measured in vitro at rest (NS, not stimulated) 
and with stimulation with LPS or IFN-γ in the absence (A) or presence 
(B) of FCS. Representative data, 3 independent experiments. Error 
bars indicate SEM.
Figure 8
Deficiency of TREM-1/3 does not abrogate in vitro neutrophil 
chemotaxis in response to chemokines. WT and TREM-1/3–deficient 
neutrophil chemotaxis was measured in response to chemoattractants 
KC (5 nM, 50 nM) and 10% ZAS. The line labeled PBS indicates the 
number of chemotactic neutrophils relative to the PBS control. Repre-
sentative data; n = 2–3 mice pooled per group; 3 independent experi-
ments. Error bars indicate SEM.
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in response to LPS or IFN-γ in the absence or presence of serum 
(Figure 7, A and B, respectively). Therefore, impaired neutrophil 
survival is likely not the mechanism of decreased neutrophil accu-
mulation in the airways of TREM-1/3–deficient animals.
In vitro chemokine-induced migration is intact in TREM-1/3–defi-
cient neutrophils. Next, we examined neutrophil migration using 
the TX migration plate (see Methods) to determine whether the 
defect in neutrophil accumulation in the airway of TREM-1/3–
deficient mice was the result of an intrinsic defect in the ability of 
TREM-1/3–deficient neutrophils to respond to chemoattractants. 
Neutrophils were placed in the upper compartment of chambers 
separated from the lower compartment by a filter with 3-μm pores. 
Zymosan-activated serum (ZAS) or CXCL-1/KC was added to the 
lower chamber as a chemoattractant. There was no significant dif-
ference in migration between WT and TREM-1/3–deficient cells 
(Figure 8), indicating that deficiency in TREM-1/3 does not alter 
the migratory response to chemoattractants.
TREM-1/3–deficient neutrophils have intact transendothelial migration. 
The first step in neutrophil migration into infected airways is neu-
trophil migration from the vasculature across the pulmonary capil-
lary endothelial cell monolayer. We hypothesized that TREM-1/3 
may interact with endothelial cell receptors to facilitate neutrophil 
migration across the endothelial cell barrier. Therefore, we examined 
whether TREM-1/3–deficient neutrophils had an impaired ability to 
cross endothelial cell monolayers in vitro. Murine endothelial cells 
lines (SVEC4-10 and murine brain endothelial cells [MBECs]) were 
seeded on 3-μm-pore-size Transwell filters and grown to confluence. 
Freshly isolated bone marrow–derived neutrophils were loaded on 
the apical side of the endothelial monolayers, and ZAS (10%), a 
neutrophil chemoattractant, was added to the opposite side. There 
was no defect in the ability of TREM-1/3–deficient neutrophils to 
migrate across murine endothelial cell monolayers as compared 
with WT neutrophils (Figure 9). In addition, we repeated the experi-
ments using primary murine endothelial cells cultured as previously 
described (26). Consistent with the cell line data, we observed simi-
lar migration of TREM-1/3–deficient and WT neutrophils across 
primary murine endothelial cell monolayers (Figure 9). These data 
suggest that impaired transendothelial migration is not the mecha-
nism of decreased neutrophils in the airway of TREM-1/3–deficient 
mice following P. aeruginosa challenge.
Figure 9
TREM-1/3–deficient neutrophils have intact transendothelial migration. 
The ability of WT and TREM-1/3–deficient neutrophils to migrate across 
murine endothelial cell monolayers (SVEC4-10 cells and MBECs) and 
primary murine lung endothelial cell monolayers was measured in 
response to stimulation with 10% ZAS. Representative data, n = 2–3 mice 
pooled per group, 3 independent experiments. Error bars indicate SEM.
Figure 10
TREM-1/3 are required for neutrophil migration across AEC monolayers. (A) TEM image the air-interface cultured primary murine airway epithelia, 
including 2 ciliated cells (C). (B) TEM image of a neutrophil (N) attached to the underside of the Transwell filter prior to migration through a pore. 
Brackets indicate the filter; arrowheads indicate each side of a pore. Scale bars: 2 μm. (C) Migration of WT and TREM-1/3–deficient neutrophils 
across WT AECs in response to KC or PBS control was measured. *P = 0.02 vs. WT neutrophil migration to KC. (D) WT and TREM-1/3–deficient 
neutrophil migration across TREM-1/3–deficient AECs was measured as in C. *P = 0.02 vs. WT neutrophil migration to KC. Representative data; 
n = 3 mice pooled per group; 2 independent experiments. Error bars indicate SEM.
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TREM-1/3–deficient neutrophils have a defect in transepithelial migration. 
In vivo, once neutrophils migrate from the capillaries, they must 
cross a pseudo-stratified epithelium to enter the luminal side of 
the airway. Airway epithelial cells (AECs) are polarized, and neu-
trophil transepithelial migration occurs from the basolateral side 
of AEC to the apical side of AEC into the airway lumen. There-
fore, the ability of TREM-1/3–deficient neutrophils to migrate 
across primary polarized AECs was examined. While TREM-1 
and TREM-3 are not known to be expressed on AECs, to elimi-
nate an AEC defect in TREM-1/3–deficient mice as the source of 
impaired migration, we cultured both WT and TREM-1/3–defi-
cient primary murine tracheal AECs on Transwells using previ-
ously described methods (27). The differentiated AECs from WT 
and TREM-1/3–deficient mice established transepithelial resis-
tance greater than 500 Ω•cm2, indicating the presence of tight 
junctions. Transmission electron micrograph (TEM) images of 
the murine airway epithelial monolayers demonstrate ciliate cell 
features (Figure 10A). Figure 10B depicts a neutrophil attached 
to underside of the Transwell filter before migration. Freshly iso-
lated bone marrow–derived neutrophils (pooled from 3 mice per 
group) were loaded on the basolateral side of AECs by inversion of 
the Transwells. CXCL1/KC was added as a chemoattractant to the 
culture medium on the apical side of the epithelium. Migration 
of WT neutrophils was similar across WT and TREM-1/3–defi-
cient AECs (P = 0.19). By contrast, TREM-1/3–deficient neutro-
phils demonstrated a significant migratory defect in response to 
CXCL1/KC across both WT (Figure 10C) and TREM-1/3–deficient 
AECs (Figure 10D). Treatment of WT neutrophils with a TREM-1 
polyclonal antibody but not a TREM-3 monoclonal antibody 
decreased migration across WT AECs (data not shown). Together, 
these data suggest that TREM-1 functions in neutrophil migra-
tion across AECs and that impaired neutrophil migration is the 
defect responsible for the susceptibility of TREM-1/3–deficient 
mice to P. aeruginosa pneumonia.
Discussion
More than 2 million people die of pneumonia annually worldwide, 
most of them children under the age of 5 (28). These deaths occur 
at extremes of the immune response: too much inflammation and 
its associated lung injury can cause death, and insufficient inflam-
mation and failure to clear infection can lead to the same result. 
Here, we identify TREM-1 as a novel receptor required for neutro-
phil transepithelial migration into the airway lumen. Our data sug-
gest a mechanism by which impaired migration results in decreased 
neutrophil recruitment and ineffective bacterial clearance. Subse-
quently, the TREM-1–deficient animals die due to excessive cytokine 
release and bacterial dissemination. Thus, potential therapeu-
tic agents to treat pneumonia, such as TREM-1 inhibitors, must 
achieve a balance between pathogen control and host tissue damage.
The neutrophil response is titrated not only through regulated 
cytokine and antimicrobial product release but also via controlled 
migration into the lung. Indeed, recent studies using intravital 
microscopy document the complexity of neutrophil migration 
(29, 30). These cells can immediately cross an endothelial cell 
barrier, pause and decide not to cross, or even cross and then 
reverse course to return to the vessel lumen, suggesting that the 
neutrophil is capable of integrating complex environmental sig-
nals (30). Determining how neutrophil migration is influenced 
by these disparate signals is critical for understanding the patho-
genesis of pneumonia, acute respiratory distress syndrome, and 
other inflammatory diseases of the lung. The role of TREM-1 
in cytokine augmentation has been well described, and our data 
demonstrate that TREM-1 is also involved in the process of neu-
trophil transepithelial migration.
Neutrophil migration into infected tissues has been studied 
extensively (31, 32). In the systemic circulation, the initial site of 
emigration is the postcapillary venule. Here, the neutrophil under-
goes capture and rolling on the endothelial surface, and selectin 
family members play a critical role (33–35). Once firm adhesion has 
been established, transendothelial migration occurs under these 
laminar flow conditions. In contrast, neutrophil migration in the 
lung occurs in the pulmonary capillaries. Here a complex web of 
anastomosing capillaries requires the neutrophil to deform in order 
to pass through the vessels (36–38). Spatial constraints in the capil-
lary most likely supplant the need for rolling and capture in the pul-
monary circulation (39), thus providing an explanation for the fun-
damental difference in neutrophil migration in the lung compared 
with the systemic circulation. On the pulmonary endothelium, 
firm adhesion is primarily mediated by the interaction between the 
β2 integrins CD18/CD11a (also LFA-1 or αLβ2) and CD18/CD11b 
(also Mac-1 or αMβ2) expressed on the neutrophils and ICAM-1 
(also CD54), ICAM-2, and ICAM-3 expressed on the endothelial 
cell surface (40–42). Both homotypic and heterotypic interactions 
between PECAM-1 (CD31), CD177, β2 integrins, ICAM-1, and 
junctional adhesion molecule (JAM) family members facilitate 
transendothelial migration (43–46). Because we observed decreased 
neutrophil accumulation in the lung airspace in TREM-1/3– 
deficient mice, we initially hypothesized that TREM-1/3 deficiency 
would cause defective transendothelial migration. However, TREM-
1/3–deficient neutrophils migrated effectively across both murine 
endothelial cell lines and primary murine endothelial cells, likely 
via these previously described pathways, suggesting that TREM-1/3 
is not required for transendothelial migration.
Compared with transendothelial migration, the molecular 
details of transepithelial migration are less well understood, 
including the extent to which neutrophils infiltrate the lung at the 
level of the large airway, the small airway, and/or the alveolar epi-
thelia. Moreover, transepithelial migration is a dynamic process, 
and neutrophil passage through the alveolar interstitium is dif-
ficult to quantitate macroscopically. Our in vitro data using large 
airway epithelia grown at the air-liquid interface support a defect 
in neutrophil transepithelial migration. However, a limitation of 
our study is that we are unable to culture alveolar epithelia at the 
air-liquid interface for in vitro testing. In our model of TREM-1/3 
deficiency, we detected differential compartmentalization of neu-
trophils in the interstitial space at the level of the small airway in 
vivo, consistent with a defect in transepithelial migration.
The integrity of the airway epithelium is achieved via tight junc-
tions and adherens junction protein interactions. Paracellular 
migration is presumably achieved through alterations in tight 
junction protein interactions. Neutrophil adherence to the pul-
monary epithelial cell layer is mediated by β2 integrins, in particu-
lar CD18/CD11b and ICAM, though CD11a and CD11c may play 
some role (47–55). The role of JAMs in intestinal transepithelial 
migration has also been studied. For example, JAM C but not JAM 
A has been implicated in intestinal neutrophil transepithelial 
migration, with studies demonstrating that JAM C antibodies 
decrease the rate of neutrophil transepithelial migration but do 
not block migration (56). Recently a role for junctional adhesion 
molecule–like protein (JAML), which is expressed on neutrophils, 
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was described in intestinal transepithelial migration (57). JAML 
binds to epithelial cell via the coxsackie and adenovirus recep-
tor (CAR), and soluble forms of either of these molecules impede 
neutrophil transepithelial migration across cultured intestinal 
epithelium. CD47, which is expressed on both epithelial cells and 
neutrophils, is also required for intestinal neutrophil transepithe-
lial migration, though the mechanism is still being characterized 
and no studies have been conducted in the lung epithelium (58). 
To date there is no evidence for an interaction between TREM-1 
and any of these adhesion molecules, suggesting that alternative 
mechanisms exist by which TREM-1 mediates neutrophil adhe-
sion and migration across epithelial cells.
In this study, we demonstrate that loss of TREM-1/3 expres-
sion results in impaired neutrophil transepithelial migration 
in a murine pneumonia model. Gibot and colleagues examined 
the role of TREM-1 in bacterial pneumonia using a different 
approach (17). Their study involved instillation of a TREM-1–
blocking peptide, LP-17, into the rat trachea following pneu-
monia challenge. Interestingly, this resulted in decreased lung 
inflammation and improved survival. Blockade of TREM-1–
mediated amplification of cytokine production was thought to 
be the mechanism behind improved survival. However, our data 
suggest that LP-17 may play a role in blocking neutrophil migra-
tion. We propose that a partial blockade of neutrophil migration 
into the airways may allow a sufficient quantity of neutrophils to 
clear the infection but prevent extensive lung injury by attenuat-
ing transepithelial migration.
In summary, our results implicate TREM-1 as a novel player in 
neutrophil pulmonary transepithelial migration. We hypothesize 
that the TREM-1 interaction with the pulmonary epithelium pro-
vides a second novel regulatory pathway in vivo for TREM-1 to 
amplify inflammation through targeted migration into lung. In 
the absence of TREM-1, in vivo neutrophil migration to the air-
way lumen is impaired. This leads to ineffective bacterial killing 
and increased mortality. Further study of the role of TREM-1/3 
molecules in transepithelial migration may identify therapeutic 
targets to modulate neutrophil influx, thereby altering the local 
inflammatory response not through classic cytokine signaling but 
through controlled migratory access.
Methods
Generation of TREM-1/3–deficient mice. To abrogate expression of functional 
TREM-1 and TREM-3 proteins, we made a targeting construct in which 
an 8.8-kb fragment containing most of exon 3 and exon 4 of TREM-1 as 
well as exon 1 of TREM-3 was replaced with an MC1neopA gene flanked 
by loxP sites (Supplemental Figure 1). This effectively deleted the trans-
membrane region of TREM-1 in addition to the start site and first domain 
of TREM-3. The targeting construct was linearized and transfected into 
E14.1 (129P2/OlaHsd) ES cells. 450 clones were chosen and expanded in 
duplicate; genomic DNA isolated from one set was digested with KpnI 
(K) and hybridized with a 3′ external probe (B) on Southern blots (endog-
enous, 13.5 kb; targeted, 17.8 kb). One correctly targeted clone was identi-
fied and confirmed by Southern blot analysis using multiple digestions 
and 5′ (A), 3′ (B), and Neo probes. This clone was injected into C57BL/6 
blastocysts; chimeras were bred to transgenic mice expressing Cre under 
the CMV promoter (59) on a C57BL/6 background to delete the MC1neo-
pA gene (TREM-1/3 del). Transmission of the TREM-1/3 deletion in 
agouti offspring was determined by PCR using tail DNA as a template 
and the following oligonucleotides: TREM-1/3 28279, TCTTGCCGCT-
GATTGGTTCA; TREM-1/3 27096, TCCCAAGAGCAGGCACAAGA; 
TREM-1/3 19239, TCTCTCCATCTATGCATCCACCC; endogenous, 
373 bp, deletion, 270 bp. Heterozygous mice were intercrossed to generate 
mice homozygous for the deletion.
Speed congenics. We backcrossed the TREM-1/3 mutation onto a C57BL/6 
background facilitated by genome-wide simple sequence length polymor-
phism (SSLP) typing at 10-cm intervals for each generation (done by the 
Speed Congenics Facility supported by the Rheumatic Diseases Core Cen-
ter at Washington University School of Medicine). The mice used for these 
experiments were >97% C57BL/6.
C57BL/6 mice were originally purchased from NCI. All animals used in 
this study were bred in a barrier facility at the University of Iowa. Mice 
used in pneumonia challenge studies were littermates or WT mice bred 
in our facility. The age of pneumonia experimental mice (55–75 days) was 
matched in WT and TREM-1/3–deficient mice. Mice used in all other 
experiments were <100 days of age.
Pneumonia models. P. aeruginosa, strain PA103, was grown overnight in LB 
broth and subcultured to mid-log phase and diluted to 2 × 105 CFU/ml. 
Mice were anesthetized with ketamine/xylazine, followed by intubation 
with a 24G catheter, and 1 × 104 CFU P. aeruginosa was instilled into the 
trachea. Mice recovered from anesthesia and were monitored for symp-
toms and temperature and euthanized when body temperature fell below 
26°C or if they were moribund. Temperatures were determined using an 
Exergen Corp. Veterinary Infrared Tympanic Temperature Scanner, Model 
VTTS-1000. Survival studies were performed on separate animals. Mice in 
survival studies received no additional treatments.
Plasma and tissue collection. Pneumonia was induced as before in separate 
groups of mice. At 14 hours after infection, mice were anesthetized, and 
blood was collected in tubes containing 10 mM EDTA. Tubes were centri-
fuged at 1,000 g for 10 minutes at 4°C. Supernatant plasma was aspirated 
and stored in multiple aliquots at –80°C until analysis. For histology or organ 
cytokine assays, lungs and liver were perfused with PBS through a catheter 
placed in the right ventricle. An opening was made in the right atrium to 
allow fluids to escape. Mouse lungs were hand homogenized in a buffer 
containing 15 mM Tris, 0.5% Triton X-100, 150 mM NaCl, 1 mM CaCl2, 
1 mM MgCl2, pH 7.4. Supernatants from homogenates were centrifuged 
at 1,000 g for 10 minutes at 4°C and stored in multiple aliquots at –80°C. 
Thawed lung homogenate supernatants were filtered through a 0.22-μm fil-
ter prior to analysis. For single-cell lung suspension analyses, perfused lungs 
were cut into small pieces and digested in 4 ml HBSS supplemented with 
60 U/ml DNase I (Sigma-Aldrich) and 125 U/ml collagenase (Invitrogen) 
for 30 minutes at 37°C. Lung tissue was pressed through a wire mesh screen 
(Cellector, Bellco Glass) following digestion to create a single-cell suspension.
Bone marrow–derived neutrophils. Mice were euthanized, and bone marrow 
was collected from femurs and tibias. Cells were isolated on a discontinuous 
Percoll gradient (MB Biomedical) composed of 81%, 62%, 55%, and 50%, and 
cells between the 62% and 81% layers were collected. Red blood cells were 
lysed with RBC Lysis Buffer (eBioscience) and neutrophils suspended in 
HBSS, without Ca2+ and Mg2+, and held on ice prior to testing. Neutrophil 
preparations were routinely >70% pure as determined by Cytospin.
Histology. At 14 hours after infection with P. aeruginosa, mice were anes-
thetized and perfused with 20 ml PBS and 20 ml 4% formaldehyde, and 
then lungs were placed in vials containing 4% formaldehyde. Lungs were 
placed under vacuum overnight, paraffin embedded, and stained with 
H&E. Histologic analysis was performed by a veterinary pathologist 
unaware of sample identities. Bilateral lungs from 5 animals in each group 
were examined. The scoring system was as follows — for cellularity (most 
severe foci assessed in lung): 1, mild, scattered leukocytes in interstitium 
and airspaces; 2, moderate, scattered leukocytes forming aggregates in 
interstitium and perivascular spaces and extending into airspaces; 3, mod-
erate to severe prominent leukocyte infiltration in interstitium extending 
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into airspaces often with prominent perivascular aggregates; for edema: 0, 
none; 1, mild, wispy eosinophilic material detectable in rare foci; 2, mild 
to moderate amounts of eosinophilic material detectable in scattered to 
coalescing foci; 3, moderate to extensive amounts of eosinophilic material 
filling alveoli. For necrotic foci, distinct necrotic cellular foci (often severely 
degenerated neutrophils with uncommon parenchymal components) in 
parenchyma were enumerated in the most severe region of each lung using 
×200 magnification fields, 2 samples/slide × 2 slides (4 samples total).
Lung scoring. Right and left lungs were sectioned in the coronal plane. 
Using a stereotactic approach, grids were used to segment the parenchyma 
into squares, and random numbers were used to identify regions for analy-
sis, except when anatomic-specific regions were assessed. All examination, 
morphometry, and scoring were done in manner blinded to treatment 
group. For bronchiole neutrophils, terminal bronchioles (TBs) were iden-
tified in sections of lung as small airways opening into alveolar ducts, and 
in each TB the number of neutrophils within the lumen and those in the 
submucosa (exterior to airway epithelium basement membrane) were enu-
merated. These were scored based on the relative proportion of neutrophils 
in each TB as follows: 1, interstitial neutrophils < luminal neutrophils; 0.5, 
interstitial neutrophils = luminal neutrophils; and 0, interstitial neutro-
phils > luminal neutrophils. For alveolar neutrophils, random sections of 
lung were assessed (×400 magnification, BX51 microscope, Olympus) for 
the number of neutrophils within alveoli, and these numbers were stan-
dardized as neutrophils per 100 alveoli (60).
BAL. At 14 hours after infection, mice were anesthetized, and the chest 
cavity was opened. The trachea was exposed, an incision made, and tubing 
inserted. The lungs were flushed with 3 × 1 ml PBS. Fluids were collected 
and volumes recorded. For bacterial counts, 100 μl fluid was removed and 
plated on LB agar as described below. The remaining fluid was centrifuged 
to remove cells, and supernatant was stored in aliquots at –80°C.
Bacterial counts. Bacterial load was determined by dilution and plate 
count on LB agar following standard microbiological methods. CFU were 
counted, and CFU/ml was calculated.
Flow cytometry. Heparinized whole blood was stained, and rbc were lysed 
with 150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA. BAL fluids were 
centrifuged and pelleted cells resuspended in 2% FBS in PBS for staining. 
BAL cells were incubated with mouse Fc Block (BD 553141) prior to addi-
tional staining. Blood and BAL were stained with anti-CD115 (eBioscience 
12-1152) and anti-Ly6G (BD 551460), which is specific for Ly6G without 
Ly6C cross-reactivity, per the manufacturer’s instructions. Cell type was 
determined by FACS on a BD LSR II with BD FACSDiva software. For 
single lung suspension analysis, a total of 2 × 106 lung cells were stained 
in a 96-well round-bottom plate. Lung homogenates were surface stained 
with mAbs specific to CD45, Ly6c, Ly6g, Siglec F (BD Biosciences), CD11c, 
F4/80, MHC II, CD4, CD8, B220, CD19, DX5, and CD3 for 30 minutes at 
4°C and fixed with FACS lysing solution (BD Biosciences) for 10 minutes 
at room temperature. All monoclonal antibodies were purchased from Bio-
Legend unless otherwise stated. Stained cells were run on a BD LSRFort-
essa. The total numbers of eosinophils (CD11cintSiglec F+), neutrophils 
(Ly6c+Ly6ghi), macrophages (CD11c+F4/80+), NK cells (CD3+DX5+), CD4+ 
T cells (CD3+CD4+), CD8+ T cells (CD3+CD8+), and B cells (CD19+B220+) 
were quantified using FlowJo (Tree Star) software.
Cytokine and chemokine assays. Plasma and BAL fluids were analyzed using 
the Milliplex Bead Assay (Millipore). Cytokines/chemokines were all quan-
tified using a customized multiplex magnetic bead panel kit (catalog MCY-
TOMAG-70K, Millipore). The manufacturer’s instructions were followed 
for assay parameters and protocol, with the following minor modification: 
50 μl BAL fluid was used instead of the recommended 25 μl. G-CSF lev-
els in mice subjected to bacterial challenge were extremely high compared 
with those of all other cytokines. Thus, G-CSF was not included in the 
multiplex panel but assayed independently at a 20-fold dilution using the 
same magnetic bead procedures. A Bio-Plex Pro II plate washer (Bio-Rad) 
was used to wash magnetic beads. Fluorescence intensity was measured on 
a Bio-Plex 200 system using Bio-Plex Manager software. Data collection 
parameters were set to 50 beads per region, 60-second timeout, bead map 
of 100 regions, sample size of 100 μl, and gate setting of 5,000–25,000.
ALT serology. ALT was determined from plasma collected as described 
above using Abaxis VetScan, Prep Profile II.
Phagocytosis assay. Murine bone marrow neutrophils were isolated as pre-
viously described and held on ice in HBSS, without Ca2+ and Mg2+. Texas 
red–zymosan particles (Molecular Probes, Invitrogen) were sonicated for 
5 minutes, opsonized in normal mouse serum in the dark for 30 minutes at 
37°C, washed, and resuspended at 0.4 M/ml in HBSS, with Ca2+ and Mg2+, 
0.1% glucose, and 1% human serum albumin. 500,000 neutrophils were 
mixed with opsonized Texas red–zymosan at MOI of 1, 5, and 25 in 100 μl 
HBSS, with Ca2+ and Mg2+, 0.1% glucose, and 1% human serum albumin. 
The mixtures were incubated at 37°C for 30 minutes, then placed on wet 
ice for 5 minutes, stained with Ly6G-FITC (BD Biosciences — Pharmingen) 
for 20 minutes on ice, and washed. FACs was performed on a BD LSR II 
with BD FACSDiva software and analyzed using Cellquest software.
Neutrophil bacterial killing. Neutrophils were isolated from bone marrow as 
described and resuspended at 6 × 105/ml in HBSS without Ca2+ and Mg2+ 
and held on ice. An overnight culture of P. aeruginosa strain PA103 was sub-
cultured until OD600 was 0.6. One milliliter of culture was pelleted at 600 g 
for 5 minutes. The pellet was resuspended in 1 ml HBSS with Ca2+ and Mg2+, 
0.5% BSA, and 10% pooled human serum and opsonized for 20 minutes at 
37°C, with rotation. Bacteria were washed twice in ice-cold PBS and resus-
pended in 1 ml HBSS with Ca2+ and Mg2+ and 0.5% BSA. Bacteria were dilut-
ed to 2.5 × 106/ml in HBSS with Ca2+ and Mg2+ and 0.5% BSA. Neutrophils 
were mixed with bacteria at 1:1 for an MOI of 1:4 and incubated together at 
37°C/5% CO2, with rotation for 45 minutes. Gentamicin sulfate (Cellgro), 
0.5 mg/ml, was added, and incubation continued for 15 minutes. The mix-
ture was washed twice in PBS to remove gentamicin and free bacteria. Neu-
trophils were resuspended in HBSS with Ca2+ and Mg2+ and 0.5% BSA and 
returned to the incubator. Samples were taken at relevant time points, and 
neutrophils were washed once in ice-cold PBS and lysed with 100 μl LB broth 
plus 0.1% Triton X-100. Plate counts were made by serial dilution on LB agar.
NADPH oxidase activity. NADPH oxidase activity was determined using 
Fluostar Omega (BMG Technologies). Neutrophils were isolated from bone 
marrow of healthy mice as described and resuspended at 1 × 106 cells/ml 
in HBSS, with Ca2+ and Mg2+, 0.1% glucose, and 0.1% human serum albu-
min. 200 μl of cell suspension with lucigenin (Sigma-Aldrich) at a final 
concentration of 100 μM was stimulated with opsonized zymosan (OpZ) 
(Molecular Probes, Invitrogen) at a ratio of 2:1 OpZ to neutrophils or 
with 10 ng/ml PMA (Sigma-Aldrich). Zymosan particles were sonicated 
for 5 minutes, opsonized by incubation with pooled human serum for 
30 minutes at 37°C, centrifuged, and resuspended in HBSS, with Ca2+ and 
Mg2+, 0.1% glucose, and 0.1% human serum albumin. Chemiluminescence 
readings were taken every minute for 60 minutes and reported as relative 
luminescence units per minute.
Cell death assay. 2 × 105 neutrophils resuspended in DMEM containing 
10% FCS or not were cultured in tissue culture wells previously coated with 
BSA (100 ng/ml BSA in PBS, 2 hours at 37°C). Cell death was determined by 
the propidium iodide uptake assay of DNA content as previously described 
(25). In brief, cells were resuspended in 0.5 ml PBS and then fixed by adding 
1.5 ml ice-cold 70% ethanol and incubating for 1 hour at 4°C. Fixed cells 
were washed once with 10 ml PBS containing 10% FCS, resuspended in the 
same buffer containing 40 μg/ml RNase A, and 50 μg/ml propidium iodide 
and incubated for 30 minutes in the dark. Samples were acquired by FACS, 
and cell death was determined based on hypodiploid DNA content.
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on the basolateral side of AECs by inverting the Transwells. KC (50 nM) 
was added at the apical side of culture medium. After 16 hours of co-
incubation, the cells in apical medium were collected and cytospinned 
on a glass microscope slide. Ly6G immunostaining was performed to 
identify neutrophils. Ly6G+ cells were quantified by counting 3 random 
fields under a ×20 objective lens.
TEM. Filters for TEM were processed using conventional methods. Brief-
ly, samples were fixed in 2.5% gluteraldehyde in 0.1 M cacodylate buffer, 
postfixed in 1% osmium tetroxide, and en bloc stained in 2.5% aqueous 
uranyl acetate. The filters were then dehydrated in a graded series of etha-
nol washes, transitioned to Eponate-12 resin (Ted Pella Inc.), and cured 
overnight at 65°C. Ultrathin sections were post-stained with uranyl acetate 
and lead citrate and imaged in a JEOL JEM 1230 transmission electron 
microscope equipped with a Gatan 2k × 2k digital camera.
Statistics. Unless otherwise noted, all data were evaluated using Graph-
Pad Prism software. Error bars represent SEM. Statistical significance was 
determined by Mann-Whitney nonparametric t test. For cytokine assays, 
geometric mean fluorescence (MF) was analyzed using a 5-parameter logis-
tic equation. Based on expected/observed concentration ratios, interpolat-
ed values greater than 10,000 pg/ml (highest concentration used for stan-
dard curve) were all arbitrarily set to 12,000 pg/ml, while values calculated 
to be less than 16 pg/ml were all set to 0. In the case of G-CSF, the upper 
limit was set to 240 ng/ml and the lower limit to 300 pg/ml. A statistical 
software package (SAS) was used to assess differences in concentrations of 
each cytokine between WT (C57BL/6) mice and TREM-1/3–deficient mice 
using the nonparametric Wilcoxon test. P values less than 0.05 were con-
sidered significant. For single lung suspension analysis, statistical analyses 
were performed using InStat software (GraphPad Software). Groups were 
compared using 2-way ANOVA with Bonferroni post-test analyses to deter-
mine whether there was a statistical significance of at least α = 0.05.
Study approval. All protocols involving mice were approved by the University 
of Iowa Institutional Animal Care and Use Committee and were carried out 
in accordance with institutional guidelines and regulations. TREM-1/3–defi-
cient animals were generated at Washington University in St. Louis with the 
approval of the Washington University Animal Care and Use Committee and 
were carried out in accordance with institutional guidelines and regulations.
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TX migration plate assay. Murine bone marrow neutrophils were isolated 
as previously described and stained with calcein-AM (Invitrogen, C3099) 
at a final concentration of 5 μg/ml. Cells were incubated at 37°C for 
30 minutes, washed, and stored in HBSS, without Ca2+ and Mg2+. Cells 
were diluted to 106/ml in HBSS, with Ca2+ and Mg2+, 0.1% glucose, and 1% 
human serum albumin prior to addition to the plate. ZAS was prepared 
by incubating normal mouse serum with sonicated zymosan (Molecular 
Probes, Invitrogen) particles at 37°C for 30 minutes (61). The zymosan 
particles were removed by centrifugation, and the resulting serum was 
diluted to 10% in HBSS, with Ca2+ and Mg2+, 0.1% glucose, 1% human 
serum albumin. KC (R&D Systems, 1395-KC) was diluted to 50 nM and 
5 nM in HBSS, with Ca2+ and Mg2+, 0.1% glucose, and 1% human serum 
albumin. DPBS without Ca2+ and Mg2+ was used to determine random 
migration. The TX migration plate (Neuroprobe, 101-3) consisted of a 
3-μm pore filter in a 96-well format. 30 μl of stimulant or PBS was placed 
in the wells below the filter. The filter was snapped in place, and 25,000 
neutrophils in 25 μl droplets were placed in hydrophobic rings on the 
filter, which allowed contact with the stimulant below. Additionally, a 
standard curve of stained cells was prepared from both cell preparations, 
and 25 μl placed in separate wells below the filter, with no fluid on the 
filter top. The prepared plate was incubated for 3 hours at 37°C/5% CO2. 
Following incubation, the cells were removed from the top of the filter 
by gently wiping with tissues and rinsing with HBSS, without Ca2+ and 
Mg2+. The plate was read on a Tecan Safire2 at 485 nm (excitation) and 
530 nm (emission). The number of migrated cells was calculated from the 
standard curves, based on relative fluorescence units, using Excel. Graphs 
were made using GraphPad Prism.
Neutrophil migration across airway endothelial cells. SVEC4-10 murine lymph 
node endothelial cells (ATCC CRL-2181) were grown in DMEM (Gibco, 
Invitrogen) supplemented with 10% FBS (Hyclone) and l-glutamine (Gibco). 
MBECs, a gift from Beverly Davidson (University of Iowa, Iowa City, Iowa, 
USA), were grown in DMEM/F12 (Gibco), supplemented with 10% FBS 
and 100 U/ml penicillin and 100 μg/ml streptomycin (Gibco). Endothelial 
cells were cultured on gelatin-coated, 3.0-μm-pore-size Transwell 
filters (Costar, 3472) for 3 days at 37°C/5% CO2 with 1 ml of medium in 
the bottom chamber. Confluence was assessed by H&E staining. Freshly 
isolated neutrophils were diluted to 5 × 106/ml in HBSS, with Ca2+ and 
Mg2+, 0.1% glucose, and 1% human serum albumin. 100 μl of neutrophil 
suspension was added to the Transwell, and 1 ml of 10% ZAS/medium 
was placed in the chamber below. Neutrophils migrated in the apical-to-
basolateral direction for 16 hours, and then were collected from the lower 
chamber and counted using a hemocytometer.
Mouse endothelial cell isolation. Murine pulmonary endothelial cells 
were isolated as previously described (26). Mice were anesthetized with 
ketamine/xylazine. The lungs were perfused with 10 ml of 2-mM EDTA in 
PBS, followed by 5 ml 0.25% trypsin/2 mM EDTA via the right ventricle. 
The lungs were removed and incubated at 37°C for 30 minutes in PBS. 
The lungs were minced with a sterile blade, suspended in 2 ml DMEM 
plus 10% FBS, and washed 10 times to elute cells from the lung. Cells, but 
not debris, were placed in a 15-ml conical tube and centrifuged 5 minutes 
at 250 g. Cells were resuspended in 1.5 ml EGB-2 medium, 2% FBS, and 
supplements (EGM-2 Bullet Kit, Lonza CC3162) and plated in two 6-well 
plates precoated with 0.2% gelatin/PBS. Medium was changed at 24 hours 
and every other day until use.
Neutrophil migration across AECs. Mouse tracheal AECs were cultured 
on 3-μm-pore-size Transwell filter (Costar, 3470) based on a previous 
report (27). Two weeks after seeding, the differentiated AECs established 
transepithelial resistance >500 Ω•cm2. To investigate the transepithelial 
migration ability of neutrophils, freshly isolated bone marrow derived 
neutrophils pooled from 3 mice per group (200,000/well) were loaded 
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